Compassion as Compound: How Preparatory Mindset Shapes the Psilocybin Experience

The Question Psychedelic Science Has Been Circling For Decades

Every serious psychedelic researcher eventually collides with the same inconvenient variable: context. Timothy Leary named it “set and setting” in the 1960s, and the phrase has survived six decades of neuroscience mostly as folklore — intuitively true, empirically thin. We know psilocybin reliably binds 5-HT2A receptors, disrupts default mode network integrity, and dissolves rigid self-models. What we’ve lacked is rigorous, longitudinal, brain-based evidence that what you do with your mind before the molecule arrives meaningfully shapes what happens after.

A new study from Carla Pallavicini, Enzo Tagliazucchi, Paul Gilbert, and colleagues at the University of Buenos Aires, CONICET, and the University of Derby’s Centre for Compassion Research and Training closes some of that gap. Published in Frontiers in Human Neuroscience (2026), the study followed 105 participants through a naturalistic psilocybin protocol, comparing two preparatory conditions: compassion imagery versus attention-to-breathing. The result isn’t just another confirmation that psychedelics change people — it’s evidence that the quality of preparatory mental training selectively amplifies specific, measurable psychological and neural outcomes.

The Design: Compassion vs. Breath as Contemplative Primers

Participants were assigned to one of two priming conditions before psilocybin administration: a compassion imagery practice — rooted in Gilbert’s compassion-focused therapy tradition, which deliberately activates what he calls “care-affiliative motivational systems” — or a more conventional attention-to-breath meditation, the default contemplative anchor in most mindfulness-based interventions. Dosing was also varied (lower and higher doses), allowing the researchers to examine dose-by-priming interactions rather than assuming psilocybin’s effects are uniform across preparatory context.

This is methodologically important. Much of psychedelic research treats “preparation” as a monolithic safety procedure — reduce anxiety, build rapport, set intentions. Here, preparation is treated as an active variable, akin to how a specific type of meditation training might interact differently with a specific neurochemical state. The researchers used self-report questionnaires alongside resting-state fMRI, collected longitudinally, to track both subjective and neural trajectories after the session.

What Changed: Absorption, Decentering, and Self-Compassion

Three findings anchor the results.

First, absorption — the capacity to become fully engaged in imaginative or sensory experience, a trait long associated with hypnotic susceptibility and meditative depth — showed sustained increases over time, and this effect was strongest in the high-dose compassion imagery condition. Absorption isn’t a fringe metric; it’s a well-validated predictor of how deeply someone engages with altered states, and its persistence post-session suggests something durable happened to participants’ capacity for present-moment engagement, not just a transient drug effect.

Second, decentering — the metacognitive ability to observe one’s thoughts and emotions as passing mental events rather than as literal truths about the self — increased within groups. Decentering is the cognitive backbone of most contemplative therapies; it’s what allows a practitioner to notice “I am having the thought that I am worthless” rather than simply believing it. Its increase here connects directly to psilocybin’s known capacity to loosen rigid self-referential processing, but the compassion priming appears to give that loosening a direction — toward more spacious self-observation rather than mere destabilization.

Third, self-compassion rose within groups as well. This is the finding with the most direct clinical resonance. Self-compassion — the capacity to hold one’s own suffering with warmth rather than harsh self-judgment — is a core deficit in depression, complex trauma, and shame-based conditions. If compassion imagery priming can nudge this trait upward and sustain the gain over time, it positions psilocybin-assisted therapy not just as a mood intervention but as a means of directly cultivating the affiliative, self-soothing capacities that many suffering people lack entirely.

The Brain Evidence: Functional Connectivity as a Classifier

The psychological self-reports are compelling, but the neuroimaging component is what elevates this from anecdote to mechanism. Using functional connectivity features derived from resting-state fMRI, the team built classifiers able to distinguish between conditions based on brain connectivity patterns alone. This means the compassion-primed and breath-primed groups weren’t just reporting different experiences — their brains showed statistically distinguishable network signatures.

This dovetails with a growing body of work — including Robin Carhart-Harris’s foundational research on the default mode network under psychedelics — showing that psilocybin’s signature neural effect is a loosening of hierarchical brain organization, particularly reduced within-network integrity of the DMN, the network most associated with self-referential narrative and rumination. What this study adds is the suggestion that the manner in which that loosening occurs — the affective and motivational quality of the mental state preceding the dose — shapes which connectivity patterns emerge and, presumably, which psychological capacities strengthen as a result.

In Digital Dharma terms, this is a striking convergence: DMN disruption is the neural correlate of ego dissolution, but ego dissolution is not a single door — it’s a hallway with multiple rooms. Compassion imagery appears to steer the traveler toward a room furnished with warmth and self-acceptance rather than mere dissolution or disorientation.

Bridging Contemplative Science and Psychedelic Neuroscience

This research sits at a genuinely interesting intersection. Paul Gilbert’s decades of work on compassion-focused therapy established that deliberately engaging care-affiliative systems — the same physiological systems implicated in oxytocin release, vagal tone, and Stephen Porges’s polyvagal framework of safety and connection — can recalibrate threat-based nervous system states into safeness-based ones. Pairing this specific contemplative technology with a 5-HT2A agonist known for radical neuroplasticity is not an accident of trial design; it’s a hypothesis about synergy. If psilocybin opens a window of heightened plasticity — consistent with BDNF-mediated mechanisms documented in other psychedelic neuroplasticity research — then what you rehearse mentally right before that window opens may get selectively reinforced as the window closes.

This is not dissimilar to findings in meditation research from labs like Richard Davidson’s and Sara Lazar’s, where the specific content of contemplative practice (loving-kindness versus focused attention versus open monitoring) produces distinguishable structural and functional brain changes over time. What Pallavicini and colleagues have done is transplant that logic into the psychedelic domain and test it longitudinally with brain imaging — a rare methodological achievement in a field still dominated by single-session, self-report-heavy studies.

Implications: Precision Priming for Psychedelic-Assisted Therapy

For practitioners and clinicians, the takeaway is concrete: preparation protocols in psychedelic-assisted therapy should not be generic. If compassion imagery reliably potentiates self-compassion and decentering — two of the most clinically valuable transdiagnostic mechanisms in mental health — then therapeutic protocols for depression, PTSD, or shame-based disorders could be intentionally paired with compassion-based priming rather than defaulting to breath-focused mindfulness, which may be better suited to anxiety or attention-related presentations.

For researchers, this study is a methodological template: treat preparatory mental training as an independent variable, not a background condition. The naturalistic sample size (105) and longitudinal fMRI design represent a substantial step beyond the small, single-session studies that have characterized much of the field’s neuroimaging literature to date.

And for the broader question of consciousness that Digital Dharma tracks across contemplative and psychedelic research — how much of the “mystical” or “ego-dissolving” psychedelic experience is pharmacology, and how much is a canvas shaped by the mind that arrives to it — this study offers a rare data point: the canvas matters. Not just for comfort or safety, but for which specific human capacities get strengthened when the ordinary self loosens its grip.

The molecule opens the door. What you were practicing on the way to it may determine which room you walk into.